Sharps injuries with Lovenox and generic enoxaparin prefilled safety syringes: A 12-year retrospective cross-sectional analytical study.

Nursing

Terry Grimmond is the director of Grimmond and Associates, Microbiology Consultancy in New Zealand; MaryAnn Gruden is an occupational health consultant in McMurray, Pa.; Bobbi Jo Hurst is an employee health and infection control RN at Orthopedic Associates of Lancaster in New Holland, Pa.; and Lydia F. Crutchfield is the President Emeritus of the Association of Occupational Health Professionals in Healthcare in Charlotte, N.C.

Published: June 2023

Purpose: Investigate the incidence and mechanisms of sharps injuries (SI) to staff using Lovenox and generic enoxaparin prefilled syringes.

Methods: Four national adverse event databases were examined over a 12-year period for incidence and brands involved with injury events to staff using enoxaparin prefilled syringes.

Results: The search revealed 581 adverse events (including 20 sharps injuries) associated with device malfunction in 8 of 16 brands, with one brand mentioned significantly more frequently than others. No national alert had been issued.

Conclusions: Use of certain brands of enoxaparin prefilled syringes poses a small but serious risk of injury to staff. Conducting root cause analyses on all SI is essential, as is the need for regularly evaluating safer devices, reporting all device incidents, enabling simpler reporting of adverse events, and establishing more effective intervention by FDA and manufacturers.

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.NURSE.0000927476.08935.e1DOI Listing

Publication Analysis

Top Keywords

enoxaparin prefilled
16
sharps injuries
12
lovenox generic
8
generic enoxaparin
8
adverse events
8
injuries lovenox
4
enoxaparin
4
prefilled
4
prefilled safety
4
safety syringes
4

Similar Publications

Sharps injuries with Lovenox and generic enoxaparin prefilled safety syringes: A 12-year retrospective cross-sectional analytical study.

Nursing

June 2023

Terry Grimmond is the director of Grimmond and Associates, Microbiology Consultancy in New Zealand; MaryAnn Gruden is an occupational health consultant in McMurray, Pa.; Bobbi Jo Hurst is an employee health and infection control RN at Orthopedic Associates of Lancaster in New Holland, Pa.; and Lydia F. Crutchfield is the President Emeritus of the Association of Occupational Health Professionals in Healthcare in Charlotte, N.C.

Purpose: Investigate the incidence and mechanisms of sharps injuries (SI) to staff using Lovenox and generic enoxaparin prefilled syringes.

Methods: Four national adverse event databases were examined over a 12-year period for incidence and brands involved with injury events to staff using enoxaparin prefilled syringes.

Results: The search revealed 581 adverse events (including 20 sharps injuries) associated with device malfunction in 8 of 16 brands, with one brand mentioned significantly more frequently than others.

View Article and Find Full Text PDF

Sharps injuries with Lovenox and generic enoxaparin prefilled safety syringes: A 12-year retrospective cross-sectional analytical study.

Nursing

June 2023

Terry Grimmond is the director of Grimmond and Associates, Microbiology Consultancy in New Zealand; MaryAnn Gruden is an occupational health consultant in McMurray, Pa.; Bobbi Jo Hurst is an employee health and infection control RN at Orthopedic Associates of Lancaster in New Holland, Pa.; and Lydia F. Crutchfield is the President Emeritus of the Association of Occupational Health Professionals in Healthcare in Charlotte, N.C.

Purpose: Investigate the incidence and mechanisms of sharps injuries (SI) to staff using Lovenox and generic enoxaparin prefilled syringes.

Methods: Four national adverse event databases were examined over a 12-year period for incidence and brands involved with injury events to staff using enoxaparin prefilled syringes.

Results: The search revealed 581 adverse events (including 20 sharps injuries) associated with device malfunction in 8 of 16 brands, with one brand mentioned significantly more frequently than others.

View Article and Find Full Text PDF

Objectives: The OVID study will demonstrate whether prophylactic-dose enoxaparin improves survival and reduces hospitalizations in symptomatic ambulatory patients aged 50 or older diagnosed with COVID-19, a novel viral disease characterized by severe systemic, pulmonary, and vessel inflammation and coagulation activation.

Trial Design: The OVID study is conducted as a multicentre open-label superiority randomised controlled trial.

Participants: Inclusion Criteria 1.

View Article and Find Full Text PDF

Anti-coagulants are one of the most important categories in healthcare therapeutics. For healthcare professionals dealing in cases of in-vivo blood clotting problems. Heparin and low molecular weight heparins (LMWHs) would be the first choice of drugs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!